Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the immunogenicity and safety of a commercially available vaccine when co-administered with GlaxoSmithKline Biologicals' HPV vaccine (580299) in healthy female subjects

Next Previous
Search
Trial Profile

Evaluation of the immunogenicity and safety of a commercially available vaccine when co-administered with GlaxoSmithKline Biologicals' HPV vaccine (580299) in healthy female subjects

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; Hepatitis B vaccine recombinant
  • Indications Cervical cancer; Hepatitis B; Human papillomavirus infections
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 01 Sep 2011 Results published in Clinical and Vaccine Immunology.
    • 01 Jul 2009 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
    • 30 Oct 2008 Planned end date changed from 1 Oct 2009 to 1 Jul 2009 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top